Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alzheimer’s Drug Discovery Foundation
New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer’s, Says the ADDF
November 18, 2026
Cognito Reports Pivotal Phase 3 Results for Spectris AD, a Non-Invasive, At-Home Approach for Alzheimer’s Treatment, Backed by ADDF Investment
November 16, 2026
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer’s Research Tool
October 28, 2026
FDA Clearance of C2N Diagnostics’ PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer’s, Building on Groundwork Laid by Early ADDF Investment
August 20, 2026